Cargando…
Tri‐modality therapy with i‐125 brachytherapy, external beam radiation therapy, and short‐term hormone therapy for high‐risk prostate cancer after holmium laser enucleation of the prostate
INTRODUCTION: We present tri‐modality therapy with i‐125 brachytherapy for high‐risk prostate cancer after holmium laser enucleation of the prostate. CASE PRESENTATION: A 75‐year‐old man had visited our hospital with complaints of dysuria. Holmium laser enucleation of the prostate was performed for...
Autores principales: | Nakiri, Makoto, Ueda, Kosuke, Ogasawara, Naoyuki, Kurose, Hirofumi, Uemura, Keiichiro, Nishihara, Kiyoaki, Muraki, Koichiro, Hattori, Chikayuki, Ogo, Etsuyo, Igawa, Tsukasa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249659/ https://www.ncbi.nlm.nih.gov/pubmed/35795117 http://dx.doi.org/10.1002/iju5.12437 |
Ejemplares similares
-
Seed lost to perineum from hydrogel spacer after brachytherapy for prostate cancer
por: Nakiri, Makoto, et al.
Publicado: (2023) -
Clinical outcomes of iodine-125 low-dose-rate brachytherapy for localized prostate cancer: a single-institution review in Japan
por: Nakiri, Makoto, et al.
Publicado: (2022) -
Analysis of radioactive implant migration in patients treated with iodine-125 seeds for permanent prostate brachytherapy with MRI-classified median lobe hyperplasia
por: Muraki, Koichiro, et al.
Publicado: (2021) -
Editorial Comment to Tri‐modality therapy with i‐125 brachytherapy, external beam radiation therapy, and short‐term hormone therapy for high‐risk prostate cancer after holmium laser enucleation of the prostate
por: Tomisaki, Ikko
Publicado: (2022) -
Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab plus Ipilimumab
por: Ueda, Kosuke, et al.
Publicado: (2023)